New treatment to protect the brain after a stroke in diabetic patients
Novel Pharmacological Approach to Stroke Neuroprotection
This study is looking at a new treatment that might help protect the brain after a stroke, especially for people with Type 2 diabetes, by using a special molecule to keep brain cells healthy and improve recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11022258 on NIH RePORTER |
What this research studies
This research investigates a novel pharmacological approach to protect the brain from damage after a stroke, particularly in patients with Type 2 diabetes. It focuses on a small molecule called CDN1163 that activates a protein known as SERCA2, which helps regulate calcium levels in brain cells. By restoring normal calcium homeostasis, the treatment aims to reduce cell death and improve recovery from stroke-related complications. The study will involve animal models to assess the effectiveness of this treatment in preventing neurovascular damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Type 2 diabetes who are at risk of or have experienced an acute ischemic stroke.
Not a fit: Patients without diabetes or those who have not experienced a stroke may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly improves recovery and reduces complications for diabetic patients who suffer a stroke.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting calcium homeostasis in stroke recovery, indicating potential for success in this novel treatment.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Lebeche, Djamel — University of Tennessee Health Sci Ctr
- Study coordinator: Lebeche, Djamel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.